Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185952 | 0.83 | PTGS2 (0.54) | PTGS2PTGS1 | |
| SCHEMBL4804927 | 0.80 | MAPT (0.48) | MAPK14METAP2 | |
| SCHEMBL6601415 | 0.78 | PTGS2 (0.59) | PTGS2PTGS1METAP2 | |
| SCHEMBL3867881 | 0.77 | PTGS2 (0.54) | PTGS2PTGS1 | |
| SCHEMBL7827933 | 0.76 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL4181720 | 0.74 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL4183493 | 0.72 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL4189225 | 0.72 | PTGS2 (0.51) | PTGS2PTGS1METAP2 | |
| SCHEMBL20818336 | 0.72 | GSTP1 (0.50) | — | |
| SCHEMBL30610192 | 0.71 | METAP2 (0.64) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |